Core Scientific (NASDAQ:CORZ) Stock Rating Reaffirmed as Buy by Canaccord Genuity Group

Core Scientific (NASDAQ:CORZ)‘s stock had its “buy” rating reissued by equities researchers at Canaccord Genuity Group in a report released on Thursday, Benzinga reports. They currently have a $36.00 price objective on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 149.13% from the company’s current price.

CORZ has been the topic of several other reports. Citigroup reissued a “market outperform” rating on shares of Core Scientific in a report on Wednesday. Rothschild & Co Redburn began coverage on shares of Core Scientific in a report on Monday, September 21st. They issued a “neutral” rating and a $16.00 target price for the company. Keefe, Bruyette & Woods upgraded shares of Core Scientific from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $25.00 to $28.00 in a report on Thursday, July 30th. Needham & Company LLC upped their price objective on Core Scientific from $29.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, B. Riley Financial increased their target price on Core Scientific from $33.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Core Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $31.36.

Core Scientific Stock Up 7.0%

Shares of CORZ traded up $0.94 during mid-day trading on Thursday, hitting $14.45. 33,742,997 shares of the company’s stock traded hands, compared to its average volume of 12,695,081. The business’s 50-day moving average price is $17.58 and its 200-day moving average price is $21.05. Core Scientific has a 1 year low of $12.31 and a 1 year high of $30.46. The firm has a market capitalization of $4.64 billion, a P/E ratio of -3.27 and a beta of 5.49.

Core Scientific (NASDAQ:CORZ) last announced its earnings results on Tuesday, July 28th. The company reported ($3.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($3.26). The firm had revenue of $164.20 million for the quarter, compared to analysts’ expectations of $144.83 million. Sell-side analysts anticipate that Core Scientific will post -1.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Core Scientific

In related news, insider Todd DuChene sold 10,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $19.97, for a total transaction of $199,700.00. Following the completion of the sale, the insider owned 1,969,101 shares in the company, valued at approximately $39,322,946.97. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders bought 19,000 shares of company stock valued at $342,290 and sold 100,000 shares valued at $1,881,300. 1.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Handelsbanken Fonder AB boosted its holdings in Core Scientific by 0.7% in the second quarter. Handelsbanken Fonder AB now owns 94,500 shares of the company’s stock worth $2,418,000 after acquiring an additional 700 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Core Scientific by 34.5% in the 2nd quarter. GAMMA Investing LLC now owns 3,049 shares of the company’s stock valued at $78,000 after buying an additional 782 shares during the period. Parkside Financial Bank & Trust boosted its position in Core Scientific by 1,371.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,177 shares of the company’s stock worth $30,000 after purchasing an additional 1,097 shares in the last quarter. Carronade Capital Management LP increased its holdings in shares of Core Scientific by 1.1% during the 1st quarter. Carronade Capital Management LP now owns 101,103 shares of the company’s stock valued at $1,513,000 after purchasing an additional 1,103 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Core Scientific by 41.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,396 shares of the company’s stock valued at $66,000 after purchasing an additional 1,285 shares in the last quarter.

Key Stories Impacting Core Scientific

Here are the key news stories impacting Core Scientific this week:

• Positive Sentiment: Analysts maintain bullish outlooks: Canaccord Genuity reaffirmed a “buy” rating with a $36 price target, while BTIG Research maintained its “buy” rating and set a $38 target. Cantor Fitzgerald also reiterated an “overweight” rating with a $39 target. These targets imply substantial upside from recent trading levels and suggest analysts remain optimistic about Core Scientific’s artificial-intelligence and high-density colocation strategy. Canaccord Genuity and BTIG analyst ratings
• Positive Sentiment: Broad Wall Street consensus remains favorable: Recent coverage includes multiple buy and overweight ratings, with a reported average price target of approximately $31.36. This reinforces the view that analysts expect significant long-term growth from the company’s transition from cryptocurrency mining toward AI and high-performance computing infrastructure.
• Neutral Sentiment: Third-quarter earnings date announced: Core Scientific will release its fiscal third-quarter 2026 results before the market opens on November 5 and hold a conference call at 8:30 a.m. Eastern time. Investors will likely focus on colocation growth, customer commitments, profitability and execution of its AI infrastructure expansion. Core Scientific third-quarter 2026 earnings announcement
• Negative Sentiment: Insider selling adds a modest cautionary signal: Insider Todd DuChene sold 10,000 shares for approximately $151,200, reducing his direct holdings by 0.85%. He still retains a large stake, so the transaction may have limited significance, but it can weigh on sentiment amid the stock’s recent weakness. Core Scientific insider sale
• Negative Sentiment: Customer credit risk remains a concern: Needham reiterated a $35 price target while noting credit pressure facing CoreWeave, a key Core Scientific tenant. Any deterioration in CoreWeave’s financial position could raise questions about customer concentration, contract stability or future expansion spending, even though Needham has not reduced its target. Needham Core Scientific price target and CoreWeave credit pressure

Core Scientific Company Profile

Core Scientific, Inc is a digital infrastructure company that develops and operates data centers in the United States. Its business has historically centered on cryptocurrency mining, particularly the processing of transactions on the Bitcoin network, while also providing hosting and infrastructure services to other mining and technology customers.

The company is expanding its data center capabilities to support high-performance computing and artificial intelligence workloads. Its services include data center operations, power and equipment management, hosting, and related infrastructure support for customers that require substantial computing capacity.

Core Scientific was founded in 2017 and became a publicly traded company through a business combination in 2022.